Lucy Scientific Discovery, Inc. · OTC:LSDIF
Lucy Scientific Discovery — IPO Roadshow (January 2023)
18 slides from Lucy Scientific Discovery's IPO roadshow presentation, Jan 18, 2023
Slide 1: Company Presentation
Company P r es e n t a t i o n CONFIDENTIAL: JANUARY 2023 Issuer Free Writing Prospectus Dated January 17 , 2023 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration No . 333 - 262296 Related to Preliminary Prospectus dated January 17 , 2023
Slide 2: Disclaimer
Disclaimer REGISTRATION STATEMENT Lucy Scientific Discovery Inc. (the “Company”) has filed a registration statement on Form S - 1 (including a preliminary prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. The registration statem
Slide 3: Key Risks
Key Risks • We have a limited operating history and have not scaled our commercial operations or made significant sales of our products or services, and we have incurred significant losses since our inception . We may continue to incur losses which, together with our limited operating history, makes
Slide 4: Offering Summary
Lucy Scientific Discovery Inc. NASDAQ: LSDI Firm Commitment Initial Public Offering Approximately $8 Million (excluding over - allotment ) Common Shares $4.00 Complete build out and make certain upgrades to manufacturing & research facilities, satisfy certain outstanding liabilities, and for working
Slide 5: Use of Proceeds & Capitalization
Use of Proceeds & Capitalization C a p i t a l iz at i o n T ab l e Su m ma r y Shares A ut ho r i ze d Shares Outstanding 1 Co m m on S h a re s Outstanding Fully Diluted % of P o t e nt ia l Fully Diluted Securities C o m mo n S h ar e s Unlimited 16,056,767 16,056,767 83 . 8 0 % Convertible Secur
Slide 6: Seasoned Team
Seasoned Team Richard Nanula • Served as CFO and EVP of Finance and Strategy at Amgen, Executive Vice President and CFO at the Walt Disney Corporation, President and COO of Starwood Hotels, and Principal at Colony Capital Director • Significant experience as board member/adviser • Vaporizer technolo
Slide 7: Board Members
Charles Nemeroff • Chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin, Dell Medical School Board Member • Served on numerous boards and councils • Expert in data protection & privacy, technology policy, and legislative reform Brittany Kaiser • Co - Fou
Slide 8: Company Overview
Company Overview What We Do We are a licensed manufacturer in Canada dedicated to the development of psychotropic and psychedelic treatment therapies addressing mental health and addiction issues. Our Mission Our mission is to become the premier contract manufacturing and research development organi
Slide 9: Investment Highlights
Investment Highlights Large Addressable Market Opportunity A variety of mental health and addiction disorders are promising candidates for psychedelic treatment therapy Regulatory Developments Public support and changing regulations for psychedelic - based therapies Health Canada Licensed Production
Slide 10: Large Addressable Market
Large Addressable Market The global psychedelics market could be worth as much as $11B in revenue by 2027 1 Addressing the Global Mental Health Crisis 2 Addressing the Global Addiction Crisis 2 S u ff er f r o m depressive disorders S u ff er f r o m a n x i et y d is o r d er s Users of tobacco pro
Slide 11: Growth Strategy
Growth Strategy Capitalize on activities that: Secure Near T e rm R e v e nu e • Sign contract manufacturing agreements with key customers • Facilitate and conduct contract psychotropic research • Achieve and maintain compliance excellence Future Growth Drivers • Meet emerging demands with innovativ
Slide 12: Regulatory Developments
Regulatory Developments Notable academic and clinical research efforts have prompted U.S. and Canadian regulatory bodies to re - evaluate various psychedelic compound classifications 1 FDA granted the Multidisciplinary Association for Psychedelic Studies (MAPS) break through therapy designation to M
Slide 13: Controlled Substance Dealer Licensed Facility
Controlled Substance Dealer Licensed Facility 25,000+ sq. ft. facility in Victoria, British Columbia 100 % Hydroelectric - powered campus, energy efficient design and equipment , compartmentalized production bays, testing and an a l yt ics l ab o rat o rie s, an d d e di c a t e d of f ice s pa c e
Slide 14: Production Capabilities
Production Capabilities Lucy is leveraging three key methods of production, with the goal of achieving best - in - class quality and facilitating market penetration through competitive pricing S y nt h es i s Natural Product Extraction Biosynthesis 14
Slide 15: Why Lucy?
W e A i m t o Be a P r e mi e r M a nu f a c t u ri n g O r g an i z a t i o n w i t h S u bsta n t i a l N ea r - A n d Lon g - T e r m G r o w t h O pp o r tu n i t i e s i n the Emerging Psychotropics Market Large Addressable Market Opportunity Health Canada Licensed Production Facility Innovativ
Slide 16: Lucy Scientific Discovery
Lucy Scientific Discovery” LUCYSCIENTIFIC.COM
Slide 17: Natural Product Extraction: Innovative Production Technology
Natural Product Extraction: Innovative Production Technology L u c y - Ve r s u s - Provides the capability to quickly scale in order to meet global market needs Minimizes reliance on external suppliers and allows for advanced drug discovery capabilities and pharmaceutical - grade outputs TerraCubeT
Slide 18: Biosynthesis Production Process
Genetic pathway for expression of desired API inserted into host cell lines Evaluate, optimize, and advance best candidates via high - throughput screening in microscale bioreactor Scale process to lab - and pilot - scale to produce gram to kilogram cGMP API quantities for research and human clinica
Lucy Scientific Discovery — IPO Roadshow (January 2023) on 6ix